Monday, August 31, 2026

CBOE Over 6% Down In The Last 21 Sessions

ViaNews Editorial Team

September 6, 2024

CBOE Over 6% Down In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 6.31% for the last 21 sessions. At 06:08 EST on Friday, 6 September, CBOE (VIX) is $22.29.

Concerning CBOE's yearly highs and lows, it's 43.53% up from its 52-week low and 36.41% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a positive 9.39%, a negative 1.31%, and a positive 6.60%, respectively.

CBOE's highest amplitude of average volatility was 12.96% (last week), 8.41% (last month), and 6.60% (last quarter), respectively.

News about

  • According to Zacks on Wednesday, 4 September, "Its current dividend yield is 2.71%, which is better than the Zacks S&P 500 composite's average of 1.25%."
  • According to FXStreet on Wednesday, 4 September, "While the S&P 500 and NASDAQ 100 have different tops for Wave (1), we anticipate Wave (2) to complete simultaneously across the SP500, DAX 40, FTSE 100, and ASX 200. "
  • According to Zacks on Wednesday, 4 September, "The Finance sector and the Zacks S&P 500 composite have returned 29.3% and 25.3%, respectively, in the same time frame. "

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com